drugset
drugset / Trial / NCT01218789

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

NCT01218789 ↗

Phase 3 Unknown 140 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.

Timeline

Start
2010-10-28
Primary completion
2024-12-05
Completion
2024-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule 20 mg Oral

Indications

non-24-hour sleep-wake syndrome